Internal link ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board March 07, 2022 at 12:00 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results February 24, 2022 at 12:00 PM UTC
Internal link ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 February 11, 2022 at 12:00 PM UTC
Internal link ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen January 04, 2022 at 12:00 PM UTC
Internal link ProQR Therapeutics Announces Results for the Third Quarter of 2014 November 24, 2014 at 12:00 PM UTC
Internal link ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares September 23, 2014 at 05:37 PM UTC